AMGen (Applied Molecular Genetics Inc.) established as a California corporation on April 8
George B. Rathmann named CEO
1983
Company changes name to Amgen
A research team led by Fu-Kuen Lin clones the gene for human erythropoietin (EPO) and produces recombinant EPO, later patented and named EPOGEN® (Epoetin alfa)
Initial Public Offering of 2,350,000 shares at $18 per share raises $40 million
1985
A research team led by Larry M. Souza clones the gene for human granulocyte colony-stimulating factor (G-CSF) and produces recombinant G-CSF, later patented and named NEUPOGEN®
1987
Amgen receives first patent on DNA used in producing Epoetin alfa
1988
Gordon M. Binder named CEO
1989
Immunex clones the gene for a soluble TNF receptor and later develops and patents a fusion product, Enbrel® (etanercept)
Amgen receives first U.S. patent for recombinant G-CSF (NEUPOGEN®)
FDA approves EPOGEN® for the treatment of anemia in patients with end-stage renal disease
EPOGEN® named "Product of the Year" by Fortune magazine
1991
FDA approves NEUPOGEN® to decrease the incidence of infection associated with chemotherapy-induced neutropenia in patients with non-myeloid cancers
Amgen establishes the Amgen Foundation for charitable giving
NEUPOGEN® named "Product of the Year" by Fortune magazine
Federal Appeals Court rules in Amgen’s favor in EPO patent dispute with Genetic Institute
1992
Amgen sales surpass $1 billion
1994
Amgen receives U.S. Department of Commerce National Medal of Technology
1996
Amgen sales surpass $2 billion
1998
FDA approves Enbrel® (etanercept) to treat patients with rheumatoid arthritis
1999
Amgen sales surpass $3 billion
FDA approves ENBREL to treat moderately to severely active polyarticular-course juvenile rheumatoid arthritis
2000
Kevin W. Sharer named CEO
2001
FDA approves Aranesp® (darbepoetin alfa) to treat anemia associated with chronic renal failure
2002
FDA approves Neulasta® (pegfilgrastim) to decrease the incidence of infection in patients with non-myeloid cancers receiving chemotherapy
FDA approves Aranesp® for the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies
Amgen completes Immunex acquisition
FDA approves Amgen’s Rhode Island manufacturing facility for ENBREL
FDA approves ENBREL to treat the signs and symptoms of active arthritis in patients with psoriatic arthritis
2003
FDA approves ENBREL for the treatment of ankylosing spondylitis and other expanded indications
2004
FDA approves Sensipar® (cinacalcet HCl) for the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis
FDA approves ENBREL for the treatment of chronic moderate to severe plaque psoriasis in adults
Amgen completes Tularik acquisition
FDA approves Kepivance™ (palifermin) to decrease the incidence and duration of severe oral mucositis in patients with hematologic cancers undergoing high-dose chemotherapy and bone marrow transplant
2006
Amgen completes Abgenix acquiston
